Introduction
Class I human leukocyte antigen (HLA-I) molecules are cellsurface-associated proteins that contain two separate polypeptide chains: a 44-kDa a (heavy) chain encoded by a major histocompatibility complex gene on the short arm of chromosome 6, and a 12-kDa b-chain (b2-microglobulin, b2M); the b2M gene resides on chromosome 15. HLA-I is expressed on the surface of almost all nucleated cells. Although the genes for the heavy chain and b2M are on different chromosomes, their expression is coordinated and cells typically express equal amounts of each protein.
Shedding from cell surfaces leads to detectable b2M in circulation. 1 Serum and plasma b2M concentrations have been reported to correlate with disease aggressiveness in certain solid tumors and hematologic diseases, primarily multiple myeloma 2 and other lymphoproliferative disorders. 3, 4 b2M concentrations in myeloproliferative diseases are less well studied, but increased levels have been associated with disease progression in chronic myelogenous leukemia, 5 acute myeloid leukemia (AML) 6, 7 and related disorders. 8 A recent study indicates that b2M, in addition to karyotype, may be a valuable prognostic marker in myelodysplastic syndrome (MDS). 9 After the discovery of free circulating HLA-I (sHLA-I) in serum, 10, 11 it has been shown that these levels are increased in patients with evidence of cellular destruction, such as those with autoimmune diseases, 12 graft versus-host disease, [13] [14] [15] acute transplant rejection, 16 viral infection 17 and proliferating tumors. 18 In vitro data indicate that increased expression of surface HLA-I on tumor cells enhances their susceptibility to the cytolytic activity of T cells. [19] [20] [21] MDS and AML are closely related and both represent neoplastic processes in bone marrow. However, they remain distinct disease entities with important biologic and clinical differences. 22 Immunomodulation plays a significant role in the biology of MDS. In fact, therapy using immunomodulators (antithymocyte globulin) has shown some success in patients with early-stage MDS. [23] [24] [25] Although classification and prognostic schemes exist, [26] [27] [28] [29] [30] variability in outcomes within AML and MDS risk categories persist, especially in patients without specific cytogenetic abnormalities.
In this study, we measured plasma levels of sHLA-I and b2M in patients with advanced MDS and AML and then examined the relationships of the levels of each marker with disease aggressiveness and various clinical manifestations. All MDS patients had advanced disease requiring chemotherapy and were treated using the same protocol that is used in the AML patients.
Patients and methods
Consecutive plasma samples from AML and MDS patients treated at the University of Texas, MD Anderson Cancer Center, were analyzed for plasma levels of b2M and sHLA-I. Samples were collected from previously untreated patients before therapy was initiated. All MDS patients were off any kind of therapy at the time of obtaining samples for analysis. However, the possibility of receiving transfusion or growth factors at earlier points cannot be ruled out. All patients with MDS had advanced disease and were candidates for chemotherapy. Advanced MDS disease is defined by the presence of severe anemia (o8 g/dl), thrombocytopenia (o50 Â 10 9 /l) or 410%
blasts. These MDS patients have a clinical outcome similar to that seen in patients with AML and were selected because our goal is to compare the biology between MDS and AML. Both AML and MDS patients were treated at MD Anderson Cancer Center with standard therapy based on idarubicine þ ara-C with minor variations (7topotecan or fludarabine). All samples were collected using Institutional Review Board-approved protocols, and all patients provided informed consent. Clinical data were collected by chart review and were part of the leukemia database at MD Anderson Cancer Center. AML and MDS were classified according to the French-American-British (FAB) system. 13, 26 Antecedent hematologic disease (AHD) was defined as a documented abnormality in the blood count present for at least 1 month before presentation. One month is defined before presenting to MD Anderson Cancer Center, irrespective of whether therapy was initiated immediately or after the waiting period. Diagnosis was made and confirmed according to FAB/ WHO criteria. Diagnosis was based on complete morphologic, immunophenotypic, cytogenetic and molecular analysis. All patients with MDS must have evidence of dysplasia in at least two lineages to be considered refractory anemia with excess of blasts (RAEB)-2 or RAEB-T. If dysplasia is not present early AML is expected. Cytogenetic status was classified as favorable (t(15;17), t (8, 21) or inv16), unfavorable (À5, À7, þ 8 or complex (X3) abnormalities) or intermediate (all others).
Also the low risk in MDS was based on AML rather than the International Prostate Symptom Score (IPSS) classification for the purpose of comparison. As patients with t(15;17), t (8;22) and inv16 are currently all considered AML, irrespective of the blast count, no patient from this group were listed in the MDS group. Performance status (PS), determined with the Zubrod scoring system, was categorized as good (0 or 1) or bad (2-4). Responders are patients who achieved complete response (CR), which is designed in patients with AML and MDS according to the International Working group criteria for CR. responders are patients who achieved CR according to the IWG criteria. [31] [32] [33] [34] b2M was measured with the commercially available kit according to the manufacturer's instructions (Immulite Diagnostic Product Corporation, Los Angeles, CA, USA). sHLA-I was measured with an enzyme-linked immunosorbent assay. Briefly, rabbit anti-mouse IgG (Sigma, St Louis, MO, USA) diluted in phosphate-buffered saline (PBS) was used to coat the wells of a microtiter plate. The wells were then blocked using 300 ml 2% non-fat milk in PBS containing 0.01% Tween-20 (PBS-Tween-20) for 1 h. The wells were washed and anti-human HLA-I W6/ 32 antibody (Sigma) was added in 0.2% non-fat milk. Plates were incubated overnight and then washed five times with PBSTween-20. The serum was diluted 1:50 in PBS-Tween-20, and 100 ml of this dilution was added to each well. Plates were then incubated with the plasma at room temperature for 2 h and washed with PBS-Tween-20. HLA-I standard control (Calibrator, Sangstat Medical Corp., Fremont, CA, USA) was diluted in PBS-Tween-20 containing 0.2% milk. For detection, plates were incubated with HRP-labeled rabbit anti-human b2M antibody (Dako, Santa Barbara, CA, USA) at room temperature for 2 h. The plates were then washed with PBS-Tween-20, and visualization was performed by adding substrate-chromogen (Dako). Colorimetric changes were measured at 450 nm within 15 min.
Measurement of annexin V
Cells were isolated using double density Histopaque 1119 and 1077 to capture both mononuclear and polymorphonuclear cells. The two cell populations were mixed, washed and stained with Annexin V and propidium iodide as recommended by the manufacturer (Becton-Dickinson, Mansfield, MA, USA). Briefly, PBS-washed cells were incubated with propidium iodine and fluorescein isothiocyanate-conjugated annexin V antibodies for 15 min, washed, processed and acquired by fluorescenceactivated cell sorting Calibur within 5 min of staining.
Statistical analysis
Patient characteristics were summarized using standard descriptive statistics for continuous variables and tabulations for categorical variables. Relationships between continuous variables were assessed with Spearman rank correlations. The w 2 test was used to assess relationships between categorical variables. Kaplan-Meier plots of survival were performed separately for each diagnostic group. Univariate Cox proportional hazards models were fit to evaluate the predictive effect of each factor alone. Factors found to be statistically significant at the 5% level in the univariate models were included in multivariate models. Multivariate models were reduced one factor at a time such that all factors remaining in the model were statistically significant at the 5% level. The Martingale residuals for continuous b2M and sHLA-1 results suggested the need for log transformation of the data. Recursive partitioning procedures were used to establish b2M and sHLA-1 cutpoints for prediction of survival in AML and MDS. Logistic regression techniques were used to model the probability of CR with b2M, sHLA-1, cytogenetic status, AHD and PS as explanatory variables. b2M and HLA-1 were investigated initially as continuous variables and then as dichotomous variables, using cutpoints calculated as described Table 1 Characteristics of AML and MDS patients sHLA-I in AML and MDS M Albitar et al above. Finally, factors found to be statistically significant in the univariate models at the 5% level were included in multivariate models. Pearson, Hosmer and Lemeshow goodness-of-fit tests were assessed for each model. Kaplan-Meier plots of cumulative response duration (CRD) were used for analysis in a fashion similar to that described for the survival analyses.
Results
The clinical characteristics of the 209 AML and 98 MDS patients included in this study are listed in Table 1 . All MDS patients had advanced disease requiring therapy (severe anemia (o8 g/dl), thrombocytopenia (o50 Â 10 9 /l) or 410% blasts). The MDS patients were treated with AML therapy, which is a standard approach at MD Anderson Cancer Center. Although there was minor variation in the idarubicine þ ara-C therapy (with or without fludarabine or topotecan), there was no significant difference in survival or CR rate between various therapy arms, as reported previously. 35 Fifty-six percent (117/209) of AML patients and 52% (51/98) of MDS patients were classified as responders.
Increased levels of sHLA-I and b2M in AML and MDS sHLA-I and b2M levels were significantly higher in AML and MDS patients than in control subjects (Po0.001), but did not differ significantly between the two disease groups. b2M and sHLA-1 levels were moderately correlated with each other in AML (Spearman r ¼ 0.46, Po0.001) and MDS (Spearman r ¼ 0.44, Po0.001) patients. Neither b2M nor sHLA-1 levels differed significantly among cytogenetic groups in either AML (Wilcoxon rank-sum test, P ¼ 0.57 and 0.25, respectively) or MDS (P ¼ 0.41 and 0.65, respectively) patients. Among AML patients, neither b2M nor HLA-1 levels differed significantly between those with and without AHD (Wilcoxon rank-sum test, P ¼ 0.43 and 0.50, respectively). In the MDS group, b2M (Wilcoxon rank-sum test, P ¼ 0.056) and sHLA-1 (P ¼ 0.077) levels were marginally higher in patients with AHD, although these differences did not reach statistical significance. Table 2 Correlation a of sHLA-I and b2M levels with laboratory variables in AML and MDS
AML MDS
sHLA-I b2M sHLA-I b2M Abbreviations: AML, acute myeloid leukemia; BUN, blood urea nitrogen; b2M, b2-microglobulin; 95% CI, 95% confidence interval; MDS, myelodysplastic syndrome; RR, relative risk; sHLA-1, soluble human leukocyte antigen-class 1.
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Correlation of b2M and sHLA-I with laboratory variables in AML and MDS
In patients with AML, sHLA-I levels correlated significantly with white blood cell (WBC) count, percentage of monocytes and lactate dehydrogenase (LDH) ( Table 2) . b2M levels correlated with these variables and with blood urea nitrogen (BUN) and creatinine (Table 2) . Correlation with LDH was weak (R-value o0.35) despite the high P-value. Neither sHLA-I nor b2M levels correlated with apoptosis (as measured by annexin V) in AML patients.
In MDS patients, sHLA-I levels correlated significantly with WBC count, percent monocytes, absolute lymphocyte counts, creatinine levels and apoptosis, but not with BUN or LDH. b2M levels correlated significantly with all variables tested except for LDH and apoptosis ( Table 2) . Levels of sHLA-I, but not b2M, correlated with apoptosis (as measured by annexin V) in patients with MDS ( Table 2) . As in AML, both sHLA-I and b2M correlated with WBC count and percentage of monocytes in PB. However, in MDS these markers also correlated with absolute lymphocyte count in PB. sHLA and b2M levels correlated with creatinine levels; b2M also correlated with BUN, but the association of sHLA-I with BUN did not reach statistical significance. ) sHLA-I levels. Kaplan-Meier survival curves were plotted, followed by log-rank test; cutpoints were established by recursive partitioning. AML patients with elevated b2M or sHLA-I levels had significantly lower survival rates over time than those with lower levels.
Correlation of sHLA-I and b2M with overall survival in AML
In univariate analysis, overall survival was significantly associated with levels of sHLA-I and b2M, regardless of whether these markers were considered as continuous or dichotomous variables (Table 3) . When cutpoints were used to dichotomize sHLA-I and b2M levels as high or low, patients with high levels of either had lower survival rates than did patients with lower levels ( Figure 1 ). As expected, overall survival was also correlated with cytogenetic abnormalities, WBC (P ¼ 0.02), LDH (P ¼ 0.047), BUN (P ¼ 0.0001) and creatine (P ¼ 0.003).
In multivariate models incorporating cytogenetics with sHLA-1 and b2M, b2M (Po0.001) but not sHLA-I (P ¼ 0.06) was retained as a significant predictor of survival, whether considered as a dichotomous (Po0.001) or as a continuous variable (Po0.001).
Cytogenetic grouping was also retained as a significant predictor of survival in both models (Po0.01). Additional multivariate models incorporating age, WBC, LDH, creatine and BUN in addition to cytogenetics did not change the conclusion.
Correlation of sHLA-I and b2M with CR in AML
As continuous variables, levels of b2M but not sHLA-I were predictive of CR (Table 4) . When cutpoints based on recursive partitioning were used, both b2M and sHLA-I were predictive of CR: patients with lower levels were more likely to respond to therapy. Cytogenetic grouping was also a significant predictor of response. Kaplan-Meier graphs were plotted, followed by log-rank test. AML patients with elevated b2M or sHLA-I had significantly worse CRD over time than those with lower levels.
Correlation of sHLA-I and b2M with CRD in AML Longer CRD was associated with lower levels of sHLA-I and b2M in univariate analysis, whether considered as continuous or dichotomous variables (Po0.001); cytogenetic status was also a predictor of CRD (Po0.001). Kaplan-Meier plots showed significant differences in CRD between patients with low and high sHLA-I levels ( Figure 2 ). In multivariate analysis using sHLA-I and b2M as continuous variables, sHLA-I (P ¼ 0.014) but not b2M levels (P ¼ 0.11) were predictive of longer CRD. However, when considered as dichotomous variables, both sHLA-I (cutpoint ¼ 420 mg/l) and b2M (3.1 gm/l) were independent predictors of longer CRD (P ¼ 0.001 and 0.036, respectively). In both multivariate models, cytogenetic status remained a significant predictor of CRD (Po0.001).
Correlation of sHLA-I and b2M with survival in MDS sHLA-I and b2M differed in their predictive value for survival in MDS patients. When considered as dichotomous variables, b2M but not sHLA-I levels were predictive of survival in univariate analysis; as continuous variables, neither sHLA-I nor b2M levels predicted survival (Table 3 , Figure 3 ). In these patients, survival correlated with cytogenetic (Table 3) and BUN (P ¼ 0.0008), but not with WBC (P ¼ 0.6), LDH (P ¼ 0.5) or creatine (P ¼ 0.3). In Figure 3 Survival in MDS according to (a) b2M and (b) sHLA-I levels. Kaplan-Meier graphs were plotted, followed by log-rank test. MDS patients with low levels of b2M had longer survival than those with elevated levels. sHLA-I level was not associated with survival in MDS.
sHLA-I in AML and MDS M Albitar et al multivariate analysis, b2M as a dichotomous variable remained an independent predictor of survival (P ¼ 0.036), as did cytogenetic status (P ¼ 0.002). Additional multivariate models incorporating age, WBC, LDH, creatine and BUN in addition to cytogenetics did not change the conclusion. As the MDS patients had advanced disease, for the purpose of comparing these patients to AML patients, we used the de novo AML cytogenetic grouping for the MDS patients rather than the IPSS grouping.
Correlation of sHLA-I and b2M with CR in MDS b2M was strongly associated with CR in univariate logistic regression analysis, whether considered as a continuous or as a dichotomous variable ( Table 4) . As a continuous variable, sHLA-I showed a marginal but not statistically significant predictive value (Table 4) . Because recursive partitioning yielded a cutpoint that divided MDS patients into one group of eight and another group of 90 patients, we did not attempt to study the predictive value of sHLA-1 as a dichotomous variable.
Correlation of sHLA-I and b2M with CRD in MDS
Univariate analysis identified only cytogenetics and elevated b2M levels (dichotomous variable at 1.8 mg/l) as significant predictors of CRD in MDS patients (P ¼ 0.03); sHLA-I was not associated with CRD, whether considered as a dichotomous or as a continuous variable (P ¼ 0.9 and 0.1, respectively). Multivariate analysis indicated that the predictive value of b2M for CRD was independent of cytogenetic grouping (P ¼ 0.04).
Discussion sHLA-1 has been shown to be shed from the surface of cells. [36] [37] [38] However, some of the sHLA-1 in circulation may result from cell turnover; the increase in apoptosis in MDS suggests that a larger portion of the sHLA-I in MDS may result from cell turnover. How circulating b2M accumulates in circulation remains less clear, but cell turnover could be the dominant mechanism.
The results of this study indicate that the prognostic significance of sHLA-I roughly parallels that of b2M in AML. In contrast, b2M but not sHLA-I is predictive of clinical behavior in MDS. Taken together, our findings point to differences in the underlying pathophysiology of AML and MDS and immune modulation is a major player in the biology of MDS disease even in the advanced stage. Obviously, biological exists overlap between the two diseases, but therapeutic approaches should be designed to address the specific molecular and biological abnormalities that underlie each disease.
The noteworthy ability of b2M and sHLA-I is to predict survival and clinical behavior in AML in an independent fashion such that it does not overlap with cytogenetic status. Either marker could be used to predict clinical behavior. This finding also supports the concept that each molecule has an independent function that is not yet defined. sHLA-I may have an advantage over b2M as a tumor marker in patients with kidney disease and elevated BUN: in these patients, elevated b2M levels could be caused by renal deficiency rather than leukemia, whereas sHLA-I levels do not correlate with BUN and do not appear to be affected by renal failure.
More importantly, as b2M is one of the two subunits that form the HLA-I molecule, we expected b2M and sHLA-I to have similar clinical relevance. This was true for AML, as described above, but not for MDS. Immunomodulation has been reported to play a role in MDS [39] [40] [41] [42] and may be a major factor in the clinical course of this disease. Thus, given that b2M and sHLA-I levels did not differ significantly between AML and MDS, a likely explanation for the discordance between these markers in predicting clinical behavior in MDS (but not AML) is the reported biological function of sHLA-I as an immune modulator owing to its inhibitory effects on cytotoxic T-lymphocytes (CTLs).
14,15 Downregulation of surface HLA-I expression in MDS may allow immune system evasion. At the same time, sHLA-I may modulate the immune response by binding to cytotoxic T cells, either inducing apoptosis or sequestering these T cells and thereby preventing them from reaching the tumor cells. Therefore, sHLA levels in MDS may reflect two opposing processes: (1) promotion of tumor growth via evasion of the immune response; and (2) modulation of the immune response by binding T lymphocytes, that are over-reactive in MDS and perhaps destroy and induce apoptosis in normal as well as in Table 4 Logistic regression analysis for complete response in AML and MDS sHLA-I in AML and MDS M Albitar et al abnormal hematopoietic cells. The latter concept is supported by the inverse correlation between apoptosis (as measured by annexin V) and sHLA-I levels, but not b2M in MDS patients. Further studies are needed to explore the potential of modulating the levels of sHLA-I in MDS patients. Furthermore, measuring the changes of both sHLA-I and b2M after therapy in such patients and correlating these changes with response may provide new insight on the mechanisms of action of these molecules and their role in AML and MDS.
In conclusion, the independent predictive value of sHLA-I and b2M in AML means that either marker may provide additional prognostic information. Because sHLA-I levels do not appear to be affected by renal impairment, this marker may be particularly useful in patients with kidney disease. In MDS, b2M but not sHLA-I can be used as a prognostic marker. sHLA-I levels may reflect immune modulation. These findings are consistent with our previous report on clinical and laboratory differences between AML and MDS. 22 
